MBX Biosciences, Inc. MBX
53.63
(1.76)
(3.18%)
as of 25 Sep
- Market cap
- $2.7B
- P/E
- 0.0×
Follow MBX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (33.17%) | (25.73%) | (27.76%) | (24.43%) |
+8 more TTM periods Free account |
|
| (31.25%) | (24.79%) | (26.61%) | (23.59%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.51%) | (19.81%) | (23.58%) | (20.78%) | |
Free Cash Flow per Share |
(1.79) | (1.71) | (2.24) | (2.31) | |
Free Cash Flow |
(85.20) | (79.81) | (81.88) | (78.91) | |
Capital Expenditures |
(2.53) | (2.34) | (1.93) | (1.23) | |
Piotroski F-Score |
2.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(9.98%) | (8.83%) | (10.76%) | (9.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.89 | 0.92 | 0.97 | |
Depreciation/Fixed assets |
0.05 | 0.08 | 0.09 | 0.12 | |
Capex/Depreciation |
(10.00) | (9.94) | (7.78) | (4.99) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.73) | (1.66) | (2.19) | (2.27) | |
Capex per Share |
(0.05) | (0.05) | (0.05) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates